Form 4: Day One Biopharmaceuticals Acquired by Servier

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals for $21.50 per share in an all-cash transaction.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) completed its merger with Servier Pharmaceuticals LLC on April 23, 2026.
• All outstanding shares of common stock were converted into the right to receive $21.50 per share in cash.
• All outstanding unvested stock options and restricted stock units (RSUs) were fully vested immediately prior to the merger.
• All equity awards were canceled and converted into the right to receive the merger consideration, minus applicable exercise prices and withholding taxes.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the merger provides a definitive liquidity event at a fixed cash price.

Positives

• Shareholders received a definitive cash exit at $21.50 per share.
• All unvested equity awards held by the reporting person were accelerated and fully vested upon the merger closing.

Negatives

• The company will no longer trade as an independent public entity following the acquisition.

Risks

• None, as the company has been acquired and is now a wholly owned subsidiary.

Future Outlook

The company is now a wholly owned subsidiary of Servier Pharmaceuticals, and no further independent public guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 6, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large pharmaceutical companies consolidating smaller, specialized biotech firms to bolster their oncology and rare disease pipelines.

Comparison to Industry Standards

• The acquisition price represents a standard premium exit for a clinical-stage biopharmaceutical company.
• The acceleration of equity vesting upon change-of-control is consistent with standard executive compensation agreements in the biotech sector.

Corporate Governance

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management see acceleration of equity vesting.

Next Steps

• Delisting of DAWN common stock from public exchanges.
• Integration of Day One Biopharmaceuticals into Servier Pharmaceuticals operations.

Key Dates

Keywords

Merger, Acquisition, Day One Biopharmaceuticals, Servier, DAWN, Form 4, Exit